Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Aust, Stefanie ^a   Auer, Katharina ^a   Bachmayr Heyda, Anna ^a   Denkert, Carsten ^b   Sehouli, Jalid ^b   Braicu, Ioana ^b   Mahner, Sven ^c   Lambrechts, Sandrina ^d   Vergote, Ignace ^d   Grimm, Christoph ^a   Horvat, Reinhard ^e   Castillo Tong, Dan C ^a   Zeillinger, Robert ^a   Pils, Dietmar ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

FAK; Immunohistochemistry; Molecular subclassification; Ovarian cancer; pFAK; Prognosis

Indexed keywords

FOCAL ADHESION KINASE;

ADULT; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER STAGING; CARCINOGENESIS; CELL STRAIN MCF 7; DISTANT METASTASIS; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING;

DISEASE-FREE SURVIVAL; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84899145162     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-67     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
3. Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control 2011, 18:8-15.
4. Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci 2012, 103:1334-1341. 10.1111/j.1349-7006.2012.02306.x, 22497737.
5. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe SC, Schlaepfer DD. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis 2012, 30:579-594.
6. Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010, 15:901-912.
7. Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, Inoue S, Yatabe Y, Takeda S, Nakao A. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol 2004, 41:104-111. 10.1016/j.jhep.2004.03.029, 15246215.
8. Rodrigo JP, Dominguez F, Suarez V, Canel M, Secades P, Chiara MD. Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007, 133:145-150. 10.1001/archotol.133.2.145, 17309983.
9. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 2012, 7:e46858. 10.1371/journal.pone.0046858, 3466197, 23056490.
10. Halder J, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005, 11:8829-8836. 10.1158/1078-0432.CCR-05-1728, 3144933, 16361572.
11. McLean GW, Avizienyte E, Frame MC. Focal adhesion kinase as a potential target in oncology. Expert Opin Pharmacother 2003, 4:227-234. 10.1517/14656566.4.2.227, 12562313.
12. Bolos V, Gasent JM, Lopez-Tarruella S, Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 2010, 3:83-97. 2895777, 20616959.
13. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994, 14:1680-1688. 358526, 7509446.
14. Golubovskaya VM, Virnig C, Cance WG. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 2008, 47:222-234. 10.1002/mc.20380, 17849451.
15. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007, 282:14845-14852. 10.1074/jbc.M606695200, 17395594.
16. Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis 2012, 33:1004-1013. 10.1093/carcin/bgs120, 3334519, 22402131.
17. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther 2010, 9:764-777. 10.4161/cbt.9.10.11434, 2933317, 20234191.
18. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 2012, 30:1527-1533. 10.1200/JCO.2011.38.9346, 22454420.
19. Fan DM, Shi HR. Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma. Int J Mol Sci 2011, 12:8489-8501. 10.3390/ijms12128489, 3257083, 22272086.
20. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004, 165:1087-1095. 10.1016/S0002-9440(10)63370-6, 1618649, 15466376.
21. Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer 2013, 23:268-275. 10.1097/IGC.0b013e31827de6b9, 23358178.
22. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232. 10.1371/journal.pmed.0050232, 2592352, 19053170.
23. Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R, Pils D. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. Mol Cancer 2012, 11:69. 10.1186/1476-4598-11-69, 3533746, 22978347.
24. Van De Wiel MA, Leday GG, Pardo L, Rue H, Van Der Vaart AW, Van Wieringen WN. Bayesian analysis of RNA sequencing data by estimating multiple shrinkage priors. Biostatistics 2013, 14:113-128. 10.1093/biostatistics/kxs031, 22988280.
25. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
27. Majewski IJ, Ritchie ME, Phipson B, Corbin J, Pakusch M, Ebert A, Busslinger M, Koseki H, Hu Y, Smyth GK, Alexander WS, Hilton DJ, Blewitt ME. Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood 2010, 116:731-739. 10.1182/blood-2009-12-260760, 20445021.
28. Gentleman R, Carey VJ, Irizarry RA, Huber W, Dudoit S. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, New York: Springer Science+Business Media.
29. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009, 28:586-604. 10.1002/sim.3495, 19051220.
30. Harrell F. Regression Modeling Strategies 2001, New York: Springer.
31. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996, 49:907-916. 10.1016/0895-4356(96)00025-X, 8699212.
32. Murata T, Naomoto Y, Yamatsuji T, Okawa T, Shirakawa Y, Gunduz M, Nobuhisa T, Takaoka M, Sirmali M, Nakajima M, Ohno Y, Tanaka N. Localization of FAK is related with colorectal carcinogenesis. Int J Oncol 2008, 32:791-796.
33. Creighton CJ. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007, 26:4648-4655. 10.1038/sj.onc.1210245, 17213801.
34. Kohn EC, Hurteau J. Ovarian cancer : making its own rules-again. Cancer 2013, 119:474-476. 10.1002/cncr.27833, 3553273, 23233093.
35. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - A study of the OVCAD consortium. Eur J Cancer 2014, 50:99-110. 10.1016/j.ejca.2013.09.011, 24176298.
36. Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, Schule R, Muller JM. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004, 24:921-927.
37. Luo M, Guan JL. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 2010, 289:127-139. 10.1016/j.canlet.2009.07.005, 2854647, 19643531.
38. Earley S, Plopper GE. Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells. Biochem Biophys Res Commun 2008, 366:476-482. 10.1016/j.bbrc.2007.11.181, 18073135.
39. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009, 28:35-49. 10.1007/s10555-008-9165-4, 19169797.
40. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007, 67:10976-10983. 10.1158/0008-5472.CAN-07-2667, 18006843.
41. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010, 9:778-790. 10.4161/cbt.9.10.11433, 2933309, 20234193.
42. Kim SH, Jang YH, Chau GC, Pyo S, Um SH. Prognostic significance and function of phosphorylated ribosomal protein S6 in esophageal squamous cell carcinoma. Mod Pathol 2013, 26:327-335. 10.1038/modpathol.2012.161, 22996377.
43. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, Meyuhas O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005, 19:2199-2211. 10.1101/gad.351605, 1221890, 16166381.
44. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013, 19:961-968. 10.1158/1078-0432.CCR-12-2243, 23307860.
45. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2013, 31:213-229. 10.1007/s10637-012-9837-3, 22661305.
46. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007, 13:252-259. 10.1016/j.molmed.2007.04.002, 17452018.